Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck